PTGS2 and myocardial infarction: In fact, safety concerns, due to the elevated risk of myocardial infarction, caused all members of selective cyclooxygenase-2 (COX-2) inhibitors, except for celecoxib, to be withdrawn from the markets in 2004 to 2005 by the United States Food and Drug Administration (FDA) [18].